AT-9283 HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529102

CAS#: 896466-61-8 (HCl)

Description: AT-9283 is a multi-targeted kinase inhibitor potentially for the treatment of multiple myeloma.


Chemical Structure

img
AT-9283 HCl
CAS# 896466-61-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 529102
Name: AT-9283 HCl
CAS#: 896466-61-8 (HCl)
Chemical Formula: C19H24ClN7O2
Exact Mass:
Molecular Weight: 417.89
Elemental Analysis: Chemical Formula: C19H24ClN7O2 Exact Mass: 417.1680 Molecular Weight: 417.8980 Elemental Analysis: C, 54.61; H, 5.79; Cl, 8.48; N, 23.46; O, 7.66

Price and Availability

Size Price Availability Quantity
500.0mg USD 2450.0 2 Weeks
1.0g USD 3250.0 2 Weeks
2.0g USD 5650.0 2 Weeks
Bulk inquiry

Related CAS #: 896466-61-8 (HCl)   896466-04-9 (free base)   896466-76-5 (lactate)    

Synonym: AT-9283; AT9283; AT 9283; AT-9283 HCl; AT-9283 hydrochloride

IUPAC/Chemical Name: 1-cyclopropyl-3-(3-(6-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea hydrochloride

InChi Key: NHFNYIVVGIXBPD-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H23N7O2.ClH/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26;/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27);1H

SMILES Code: O=C(NC1=CNN=C1C2=NC3=CC=C(CN4CCOCC4)C=C3N2)NC5CC5.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 417.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Matsueda S, Gao H, Efferson CL, Tsuda N, Ishiyama S, Li Y, Ioannides MG, Fisk B, Peoples GE, Ioannides CG. N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35. PubMed PMID: 19596910.

2: Li Y, Matsueda S, Efferson CL, Tsuda N, Kawano K, Gao H, Peoples GE, Ioannides CG. Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines. Anticancer Res. 2009 Jan;29(1):41-58. PubMed PMID: 19331132.

3: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Sep;32(7):517-48. doi: 10.1358/mf.2010.32.7.1549223. PubMed PMID: 21069103.

4: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346.

5: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PubMed PMID: 19088949.

6: Díaz-Ortega JL, Bennett JV, Castañeda-Desales D, Quintanilla DM, Martínez D, de Castro JF. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection. Vaccine. 2014 Jun 17;32(29):3680-6. doi: 10.1016/j.vaccine.2014.04.031. PubMed PMID: 24837512.

7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40. PubMed PMID: 17235418.

8: Xu J, You C, Zhang S, Huang S, Cai B, Wu Z, Li H. Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice. J Neurosurg. 2006 Oct;105(4 Suppl):306-10. PubMed PMID: 17328281.

9: Papacchini F, Goracci C, Sadek FT, Monticelli F, Garcia-Godoy F, Ferrari M. Microtensile bond strength to ground enamel by glass-ionomers, resin-modified glass-ionomers, and resin composites used as pit and fissure sealants. J Dent. 2005 Jul;33(6):459-67. PubMed PMID: 15935265.

10: Vamvakidès A. [Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine (AE37): common action mechanism?]. Ann Pharm Fr. 2002 Mar;60(2):88-92. Review. French. PubMed PMID: 11976553.

11: Gündoğdu C, Arslan R, Arslan MO, Gicik Y. [Evaluation of cystic and alveolar echinococcosis cases in people in Erzurum and surrounding cities.]. Turkiye Parazitol Derg. 2005;29(3):163-6. Turkish. PubMed PMID: 17160814.

12: Shinagawa K, Tachihara R, Matsusaka N, Sugii S. Immunological cross-reactivity of the fragments of staphylococcal enterotoxins A and E generated by digestion of proteolytic enzymes. J Vet Med Sci. 1991 Apr;53(2):223-7. PubMed PMID: 1713793.

AT-9283 HCl

500.0mg / USD 2450.0